Translational Regenerative Medicine: Market Prospects 2016-2026

Feb 08, 2016, 09:00 ET from Visiongain

LONDON, February 8, 2016 /PRNewswire/ --

Can Promising Therapies in Stem Cells, Tissue Engineering and Gene Therapy Change the Way We Treat Rare and Chronic Diseases?

What can be expected from the Translational Regenerative Medicine market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 285-page report provides 170 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of translational regenerative medicine market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Translational regenerative medicine submarkets:
• Stem Cell Therapies
• Tissue Engineering
• Gene Therapies

See revenue forecasts for some the leading products in the market
How will leading drug perform to 2026? Our study forecasts revenues for a number of leading products in the translational regenerative medicine market including:
• Osteocel Plus
• Trinity ELITE
• TEMCELL /Prochymal
• Apligraf
• Dermagraft
• ReCell
• Neovasculgen
• Glybera (alipogene tiparvovec)
• IMLYGIC (talimogene laherparepvec)

See revenue forecasts for the leading regional markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• Rest of World

Leading companies and potential for market growth
Overall revenue for the Translational Regenerative Medicine market will reach $12.1bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.

Our work analyses the key companies in the market. See Visiongain's analysis of 16 leading companies, including these:
• Alphatec Spine
• Anterogen
• Athersys
• Avita Medical
• AxoGen
• Medipost
• Mesoblast
• NuVasive
• Ocata Therapeutics
• Organogenesis
• Osiris Therapeutics
• Pharmicell
• Regenersys
• TiGenix
• UniQure
• Vericel Corporation

A company profile gives you the following information where available:
• Discussion of a company's activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect translational regenerative medicine industry?
Our new report discusses issues and events affecting the translational regenerative medicine market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Changing regulatory landscape challenging new entrants and major market players alike
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Translational Regenerative Medicine: Market Prospects 2016-2026 report helps you
In summary, our 285-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Translational Regenerative Medicine market - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket - discover prospects for leading translational regenerative medicine products in the following areas: stem cell therapies, tissue engineering and gene therapy.
• Revenue forecasts to 2026 for 9 of the leading products in the Translational Regenerative Medicine market - discover prospects for leading translational regenerative medicine products including: Osteocel Plus, Trinity ELITE, TEMCELL /Prochymal, Apligraf, Dermagraft, ReCell, Neovasculgen, Glybera (alipogene tiparvovec) and IMLYGIC (talimogene laherparepvec)
• Revenue forecasts to 2026 for one leading national market and two leading regional markets - US, Europe, Asia-Pacific and Rest of World
• Assessment of 16 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the translational regenerative medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

Companies Mentioned in  the Report

Advanced BioHealing

Advanced Tissue Sciences



AlphaTec Spine




Amorepacific Group

AnGes MG

Angioblast Systems

Anika Therapeutics



Arcarios B.V

Ark Therapeutics

Athersys Inc

Avita Medical



Beike Biotechnology

Benda Pharmaceutical



BioMed Realty Trust, Inc

BioSante Pharmaceuticals


BioTissue AG

BioVex Inc

Blackstone Medical

BrainStorm Cell Therapeutics

Caladrius Biosciences

California Stem Cell Inc




Cell Targeting

CellCo Tec

Cellerant Therapeutics



CHA Biotech

Chiesi Farmaceutici


Co.don AG

Cold Genesys

Cook Biotech Inc


Cytori Therapeutics

Daiichi Sankyo

DePuy Mitek (Johnson & Johnson)

FibroCell Science

Gamida Cell Ltd

Genzyme Corporation (Sanofi)



Human Stem Cell Institute

Insulete Inc

Interxon Corporation

ISTO Technologies

Janssen Biotech Inc

Japan Tissue Engineering Co

JCR Pharmaceuticals

Johnson & Johnson

Kinetic Concept Inc

LecTec Corporation

Lincoln Park Capital






Mitsubishi Tanabe

Myriad Genetics



Nippon Zoki Pharmaceuticals


Ocata Therapeutics



Orphan Biovitrum AB (Sobi)


Orteq Ltd.

Osiris Therapeutics

Oxford BioMedica

Parcell Laboratories




Reliance Life Sciences


RTI Surgical

Rusnano Corporation

Sangamo Biosciences


Shanghai Sunway Biotech

Shenzhen Sibiono GeneTech


Singapore General Hospital

Skye Orthobiologics

Smith & Nephewbv

Sobi Partners

Spark Therapeutics

StemCells Inc.

Stempeutics Research

Stratatech Corporation

TCA Cellular Therapy

Tengion Inc

Teva Pharmaceuticals



U.S. Stem Cell Inc.

Vericel Corporation

Viacyte Inc

Vital Therapies

WKD Holding Oy


Xenetic Biosciences


Organisations Mentioned in  the Report  

Arthritis Research UK

Associazione Infermieristica per lo Studio delle Lesioni Cutanee (AISLeC) [China]

Australian Regenerative Medicine Institute

Australian Sports Anti-Doping Authority (ASADA)

Biomedical Advanced Research and Development Authority (BARDA)

British Heart Foundation [UK]

California Institute of Regenerative Medicine (CIRM)

Cambridge Stem Cell Biology Institute [UK]

Case Western Reserve University

Catalan Institution for Research and Advanced Studies

Center for Biologics Evaluation and Research (CBER) [US]

CHA General Hospital [Korea]

Cryocenter Saint Petersburg

Drugs Controller General of India (DCGI)

European Group for Blood and Marrow Transplantation (EBMT)

European Medicines Agency

Food and Drugs Agency (FDA) [US]

Haute Autorité de santé [France]

Heriot-Watt University

Human Fertilisation and Embryology Authority (HFEA)

Institute of Biomedical Research and Innovation Hospital [Japan]

International Society for Stem Cell Research (ISSCR)

Karolinska Institute [Sweden]

Massachusetts General Hospital (MGH)

Mayo Clinic [US]

Medical Research Council [UK]

Ministry of Food and Drug Safety, MFDS) [Korea]

Ministry of Health, Labour and Welfare (MHLW) [Japan]

Ministry of Science and Technology [China]

Moorfields Eye Hospital

National Tissue Engineering Center (NTEC) [China]

New York Blood Center

Riken Center for Developmental Biology

RUSH University Medical Center [US]

Russian Ministry of Healthcare and Social Development

Scottish Centre for Regenerative Medicine

St. Jude's Children Research Hospital

State Food and Drug Administration (SFDA) [China]

SUNY Upstate Medical University

The Genetico Center [Russia]

The StemGen Organisation

Therapeutics Goods Administration (TGA) [Australia]

UH San Diego Sanford Stem Cell Clinical Center

UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Universitat Autònoma de Barcelona [Spain]

University College London

University of Edinburgh MRC Centre for Regenerative Medicine [UK]

University of Massachusetts (UMass) Memorial Hospital

University of Modena Centre for Regenerative Medicine [Italy]

University of Wisconsin

US National Institute of Health

Wake Forest Institute

Wellcome Trust

World Health Organization

Yale School of Medicine

To request an exec summary of this report please email Sara Peerun at or call Tel: +44(0)-20-7336-6100

Or click on

SOURCE Visiongain